| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1042579421 |
| P356 | DOI | 10.2165/00003088-198712030-00002 |
| P698 | PubMed publication ID | 3555940 |
| P2093 | author name string | Christensen ML | |
| Crom WR | |||
| Evans WE | |||
| Relling MV | |||
| Rodman JH | |||
| Glynn-Barnhart AM | |||
| Kavanagh RE | |||
| Teresi ME | |||
| P2860 | cites work | The role of metabolic activation by cytochrome P-450 in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins | Q93646822 |
| Prednisone side-effects and serum-protein levels. A collaborative study | Q93709903 | ||
| Release of free bases from deoxyribonucleic acid after reaction with bleomycin | Q93729778 | ||
| Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients | Q93731864 | ||
| Action of bleomycin on DNA and RNA | Q93733024 | ||
| INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE | Q28202030 | ||
| Dose-response effect of adjuvant chemotherapy in breast cancer | Q28283048 | ||
| Risk factors for doxorubicin-induced congestive heart failure | Q28328220 | ||
| Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity | Q28329409 | ||
| Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases | Q28330575 | ||
| Alkylating properties of phosphoramide mustard | Q28341980 | ||
| Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products | Q28582224 | ||
| 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations | Q33334254 | ||
| Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases | Q33342636 | ||
| Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum | Q33458060 | ||
| Phase II trial of vincristine infusion in acute leukemia | Q33459149 | ||
| Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function | Q33477777 | ||
| Intensive chemotherapy of small cell bronchogenic carcinoma | Q34017688 | ||
| Drugs five years later. Cisplatin | Q34257493 | ||
| Biliary excretion of vincristine | Q34263753 | ||
| Oral prednisone for chronic active liver disease: dose responses and bioavailability studies | Q34475234 | ||
| Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target Tissues | Q34508535 | ||
| Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration | Q34518084 | ||
| The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy | Q34519153 | ||
| Adriamycin. A new anticancer drug with significant clinical activity | Q34699440 | ||
| The pharmacokinetics of daunomycin in man | Q34704151 | ||
| Effect of chelating agents and metal ions on the degradation of DNA by bleomycin | Q34725946 | ||
| Biliary excretion of platinum in a patient treated with cis-dichlorodiammineplatinum (II). | Q35570007 | ||
| Methotrexate in Liver and Bile after Intravenous Dosage in Man | Q36040346 | ||
| Synthesis, Retention, and Biological Activity of Methotrexate Polyglutamates in Cultured Human Breast Cancer Cells | Q37016158 | ||
| Treatment of Burkitt's tumor with cyclophosphamide | Q38896216 | ||
| Adriamycin metabolism in man. Evidence from urinary metabolites | Q39082453 | ||
| The changing management of childhood Hodgkin's Disease | Q39313930 | ||
| Phase II evaluation of bleomycin.A Southwest Oncology Group study | Q39390882 | ||
| Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion | Q39460909 | ||
| Chemotherapy of acute leukemia in childhood. Comparison of cyclophosphamide and mercaptopurine | Q72797097 | ||
| Cyclophosphamide hemorrhagic cystitis | Q72887597 | ||
| VP-16-213 (etoposide): the mandrake root from Issyk-Kul | Q72922138 | ||
| The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man | Q74786929 | ||
| FURTHER COMPARATIVE TRIAL OF TRIETHYLENE THIOPHOSPHORAMIDE AND MECHLORETHAMINE IN PATIENTS WITH MELANOMA AND HODGKIN'S DISEASE | Q76688739 | ||
| CYCLOPHOSPHAMIDE THERAPY IN CHILDHOOD NEUROBLASTOMA | Q76793131 | ||
| CLINICAL STUDIES OF DICHLOROMETHOTREXATE (NSC 29630) | Q78342759 | ||
| Cyclophosphamide therapy in children with Ewing's sarcoma | Q79624491 | ||
| Determination of etoposide (VP16-213) and teniposide (VM-26) in serum by high-performance liquid chromatography with electrochemical detection | Q79987285 | ||
| Vincristine neurotoxicity | Q93578686 | ||
| Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity | Q93609846 | ||
| Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II) | Q93615966 | ||
| Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin | Q69994799 | ||
| Letter: Non-specific enhancement of glomerular filtration by corticosteroids | Q70032640 | ||
| Pharmacokinetics of teniposide in patients with ovarian cancer | Q70048967 | ||
| The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy | Q70058397 | ||
| Bioavailability and pharmacokinetics of etoposide (VP-16) | Q70065661 | ||
| Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro | Q70070352 | ||
| Pharmacokinetics of etoposide in gestochoriocarcinoma | Q70077677 | ||
| Variable bioavailability following repeated oral doses of etoposide | Q70118152 | ||
| Clinical pharmacokinetics of intraarterial cisplatin in humans | Q70192268 | ||
| Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients | Q70201995 | ||
| Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid | Q70341284 | ||
| Pharmacokinetics of VP16-213 given by different administration methods | Q70367546 | ||
| Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer | Q70367549 | ||
| Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? | Q70367553 | ||
| Cyclophosphamide pneumonitis | Q70379730 | ||
| The anticancer agent adriamycin can be actively cytotoxic without entering cells | Q70383981 | ||
| Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methylmethotrexate | Q70397051 | ||
| The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination | Q70424991 | ||
| Bioavailability of methotrexate tablets | Q70436219 | ||
| Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern | Q70482286 | ||
| Protein binding of anthraquinone glycosides, with special reference to adriamycin | Q70561502 | ||
| The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle | Q70583860 | ||
| Methotrexate Pharmacokinetics | Q70620597 | ||
| Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients | Q70641866 | ||
| The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy | Q70648634 | ||
| Quantitative changes in cis-dichlorodiammineplatinum(II) speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results | Q70648636 | ||
| Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II) | Q70650281 | ||
| Urinary metabolites of the antitumor agent cyclophosphamide | Q70652558 | ||
| Clinical kinetics on intact cisplatin and some related species | Q70660296 | ||
| Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II) | Q70665975 | ||
| Cisplatin disposition in children and adolescents with cancer | Q70667286 | ||
| Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study | Q70669132 | ||
| Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors | Q70792126 | ||
| The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate | Q70792552 | ||
| Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolit | Q70920666 | ||
| Pharmacokinetics of vincristine infusion | Q70970102 | ||
| Pharmacokinetics of Sustained Serum Methotrexate Concentrations Secondary to Gastrointestinal Obstruction | Q70978443 | ||
| Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion | Q70982842 | ||
| Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy | Q70992219 | ||
| Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system | Q71186764 | ||
| The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol | Q71201433 | ||
| Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration | Q71208328 | ||
| Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study | Q69848274 | ||
| Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy | Q69870731 | ||
| Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide | Q69885791 | ||
| Methotrexate: bioavailability and pharmacokinetics | Q69899431 | ||
| Inactivation of phi X174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213 | Q69982348 | ||
| Hypoalbuminemia in patients receiving cisplatin: correlation between liver platinum and decrease in serum albumin | Q69991731 | ||
| Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay | Q39465511 | ||
| Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma | Q39465516 | ||
| Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus | Q39470295 | ||
| Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives | Q39477350 | ||
| Etoposide (VP-16-213). Current status of an active anticancer drug | Q39492961 | ||
| The pharmacokinetics of bleomycin in man. | Q39497594 | ||
| Properties and products of the degradation of DNA by bleomycin and iron(II) | Q39505183 | ||
| Improved therapeutic index of bleomycin when administered by continuous infusion in mice | Q39547610 | ||
| Catalytic release of deoxyribonucleic acid bases by oxidation and reduction of an iron .cntdot. bleomycin complex | Q39566616 | ||
| Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide | Q39687321 | ||
| Clinical Pharmacokinetics of Methotrexate1 | Q39720628 | ||
| Preclinical selection of new anthracyclines. | Q39726430 | ||
| Vincristine neurotoxicity. Pathophysiology and management. | Q39752416 | ||
| Age-related adriamycin cardiotoxicity in children | Q39770642 | ||
| Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations | Q39798597 | ||
| Mechanism of action of cis-dichlorodiammineplatinum(II) | Q39811884 | ||
| Podophyllotoxin derivative VP 16-213 | Q39825232 | ||
| A clinical review of bleomycin--a new antineoplastic agent | Q39868693 | ||
| Pharmacokinetics of cyclophosphamide in man | Q39986730 | ||
| Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients | Q40026026 | ||
| Mechanism of bleomycin action: studies | Q40100228 | ||
| The renal toxicity of cancer chemotherapeutic agents | Q40102843 | ||
| Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent | Q40141842 | ||
| The pharmacology and clinical use of methotrexate | Q40158601 | ||
| The importance of dose intensity in chemotherapy of metastatic breast cancer | Q40190080 | ||
| Cisplatin: chemistry, distribution and biotransformation | Q40307098 | ||
| The clinical pharmacology of VM26 and VP16-213. A brief overview | Q40331917 | ||
| The podophyllotoxin derivatives VP16-213 and VM26. | Q40331927 | ||
| Current development of podophyllotoxins | Q40331944 | ||
| Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma | Q40585977 | ||
| Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro | Q40618885 | ||
| "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment | Q40650547 | ||
| High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity | Q40653373 | ||
| Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity | Q40655039 | ||
| Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models | Q40666022 | ||
| Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue | Q40666027 | ||
| Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients | Q40733350 | ||
| Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia | Q40831494 | ||
| Pyrogenic properties of bleomycin (NSC-125066). | Q40909007 | ||
| Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis | Q41442106 | ||
| Decreased half life of cyclophosphamide in patients under continual treatment | Q41445391 | ||
| Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents | Q41558822 | ||
| DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. | Q41605393 | ||
| Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate | Q41617540 | ||
| Testis cancer in children | Q41653247 | ||
| Anthracycline antibiotic pharmacology and metabolism | Q41673593 | ||
| The effect of dose on the bioavailability of oral etoposide. | Q42025055 | ||
| Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen | Q42201490 | ||
| The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. | Q42228926 | ||
| Can severe vincristine neurotoxicity be prevented? | Q42241620 | ||
| Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia | Q42261326 | ||
| Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion | Q42263291 | ||
| Pharmacokinetics and metabolism of vinblastine in humans | Q42596745 | ||
| Bleomycin disposition in children with cancer | Q42664850 | ||
| Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells | Q44742112 | ||
| Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules | Q44842215 | ||
| Bilary disposition of adriamycin | Q44912291 | ||
| Drug dosage and remission duration in childhood lymphocytic leukemia | Q44949634 | ||
| Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture | Q45032099 | ||
| Clinical trials with bleomycin in lymphomas and in solid tumors | Q45253057 | ||
| Metabolism of folate antagonists | Q46969807 | ||
| Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. | Q47255834 | ||
| Clinical pharmacology of cyclophosphamide | Q48012175 | ||
| PTG, a new antineoplastic epipodophyllotoxin | Q48447875 | ||
| Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report | Q48542836 | ||
| Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule | Q48590767 | ||
| Etoposide-induced blood-brain barrier disruption. Effect of drug compared with that of solvents | Q48617699 | ||
| The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt | Q48667726 | ||
| Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice | Q48798919 | ||
| Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors | Q48941626 | ||
| Hearing loss in children receiving cisplatin chemotherapy. | Q50593438 | ||
| Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. | Q50597553 | ||
| Cis-platinum vestibular toxicity. | Q50602001 | ||
| Pharmacokinetics of oral methotrexate in children. | Q51647048 | ||
| Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? | Q51657521 | ||
| Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. | Q52433291 | ||
| Dose dependent pharmacokinetics of prednisone and prednisolone in man | Q52435132 | ||
| Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans | Q52437503 | ||
| Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. | Q52659462 | ||
| Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma. | Q52680277 | ||
| Teniposide (VM26) disposition in children with leukemia. | Q52695550 | ||
| Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. | Q52717765 | ||
| Methotrexate tissue distribution: prediction by a mathematical model | Q53002760 | ||
| Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. | Q53749107 | ||
| Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma | Q53751603 | ||
| Tissue effects of glucocorticoids. | Q53889830 | ||
| Doxorubicin and cisplatin excretion into human milk. | Q54323484 | ||
| Evidence for the involvement of two distinct membrane proteins in adriamycin resistance in Chinese hamster lung cells. | Q54440017 | ||
| Effect of route of administration and effusions on methotrexate pharmacokinetics. | Q54451334 | ||
| New chemistry of an old molecule: cis-[Pt(NH3)2Cl2]. | Q54456248 | ||
| Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma. | Q54457007 | ||
| The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells. | Q54503263 | ||
| Membrane alterations associated with progressive adriamycin resistance. | Q54513517 | ||
| Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. | Q54529667 | ||
| Prednisolone disposition in steroid-dependent asthmatic children. | Q54537728 | ||
| Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II). | Q54579966 | ||
| Haemodialysis during cyclophosphamide treatment. | Q55153787 | ||
| Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol. | Q55488920 | ||
| Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. | Q55488959 | ||
| Etoposide pharmacokinetics in patients with normal and abnormal organ function | Q57223635 | ||
| Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage | Q64390537 | ||
| Interaction of probenecid with the protein binding of methotrexate. | Q64915838 | ||
| Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours | Q66904658 | ||
| The adverse effect of anticonvulsant therapy on renal allograft survival. A preliminary report | Q66904991 | ||
| Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity | Q71228108 | ||
| The effect of organic acids on renal clearance of methotrexate in man | Q71232539 | ||
| Clinical pharmacology of intermediate-dose oral methotrexate | Q71236275 | ||
| A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy | Q71248649 | ||
| Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients | Q71250337 | ||
| Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine | Q71250375 | ||
| Interactions between 7-hydroxymethotrexate and methotrexate at the cellular level in the Ehrlich ascites tumor in vitro | Q71256714 | ||
| Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro | Q71256719 | ||
| A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients | Q71274944 | ||
| Metabolism of methotrexate in man after high and conventional doses | Q71279373 | ||
| Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship | Q71320557 | ||
| Effect of penicillin on the renal tubular secretion of methotrexate in the monkey | Q71321785 | ||
| Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption | Q71324292 | ||
| Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer | Q71393873 | ||
| A study of the distribution of methotrexate in human tissues and tumors | Q71454654 | ||
| PLasma half-life and urinary excretion of cyclophosphamide in children | Q71470408 | ||
| Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies | Q71474529 | ||
| Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide | Q71509201 | ||
| Phase I and preliminary phase II evaluation of adriamycin (NSC 123127) | Q71579286 | ||
| Interaction of methotrexate metabolites with beef liver dihydrofolate reductase-I. Binary complex study | Q71701930 | ||
| Test dose for predicting high-dose methotrexate infusions | Q71727462 | ||
| Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction | Q71758075 | ||
| Age dependence of the early-phase pharmacokinetics of doxorubicin | Q71788754 | ||
| Doxorubicin in pregnancy: possible transplacental passage | Q71821522 | ||
| Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment | Q71822474 | ||
| Pharmacokinetic modeling of cisplatin disposition in children and adolescents with cancer | Q71845073 | ||
| Human tissue distribution of platinum after cis-diamminedichloroplatinum | Q71845078 | ||
| Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications | Q71845152 | ||
| Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate | Q72049096 | ||
| Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia | Q72057965 | ||
| Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia | Q72063971 | ||
| Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy | Q72075028 | ||
| High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma | Q72075807 | ||
| Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia | Q72098080 | ||
| Methotrexate in the plasma and cerebrospinal fluid of children treated with intermediate dose methotrexate | Q72101269 | ||
| Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy | Q72107629 | ||
| Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II | Q72397901 | ||
| Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia | Q72571805 | ||
| Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion | Q72626640 | ||
| Prospective study of the pulmonary toxicity of continuously infused bleomycin | Q72636030 | ||
| Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo | Q72651598 | ||
| Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro | Q72672900 | ||
| Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity | Q72689111 | ||
| In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells | Q72708588 | ||
| Pharmacokinetics of Anticancer Drugs in Children | Q72720181 | ||
| Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro | Q72738256 | ||
| Pharmacokinetics of vincristine sulfate in adult cancer patients | Q42671013 | ||
| Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients | Q42671020 | ||
| Pharmacokinetics of vincristine sulfate in children | Q42671215 | ||
| Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives | Q43406881 | ||
| Renal function and the rate of disappearance of methotrexate from serum | Q43492583 | ||
| Inhibition of renal tubular transport of methotrexate by probenecid | Q43911534 | ||
| Comparison of serum concentrations of methotrexate after various routes of administration | Q43982160 | ||
| Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance | Q44201992 | ||
| Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo | Q44341452 | ||
| Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model | Q44430214 | ||
| High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity | Q44502873 | ||
| Effect of pleural effusion on high-dose methotrexate kinetics | Q44576946 | ||
| Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II) | Q66957072 | ||
| Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory | Q66992158 | ||
| The disposition of cyclophosphamide in a group of myeloma patients | Q66992161 | ||
| Chemotherapy of sarcomas | Q67241643 | ||
| EPEG, a new antineoplastic epipodophyllotoxin | Q67244197 | ||
| Investigations of the metabolic fate of tritiated vincristine in the rat by high-pressure liquid chromatography | Q67247890 | ||
| Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy | Q67249744 | ||
| Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man | Q67314024 | ||
| Kinetics and Interconversion of Prednisolone and Prednisone Studied with New Radioimmunoassays | Q67315545 | ||
| Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man | Q67376445 | ||
| Non-Hodgkin's lymphoma in children | Q67395147 | ||
| Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells | Q67431076 | ||
| Kinetics of cis-dichlorodiammineplatinum | Q67467904 | ||
| Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay | Q67540791 | ||
| Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding | Q67567585 | ||
| Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model | Q67567829 | ||
| Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function | Q67567851 | ||
| Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity | Q67598957 | ||
| The pharmacokinetics of [3H]-vincristine in man | Q67674473 | ||
| Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols | Q67746105 | ||
| Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia | Q67756242 | ||
| Clinical effects and pharmacokinetics of different dosage schedules of adriamycin | Q67764510 | ||
| Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs | Q67796284 | ||
| Drug interaction in psoriasis | Q68260251 | ||
| The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man | Q68552830 | ||
| Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors | Q68700939 | ||
| Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect | Q68719349 | ||
| Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes | Q68792263 | ||
| Daunorubicin metabolism in acute myelocytic leukemia | Q68993999 | ||
| Clinical and pharmacological studies with cis-diamminedichloroplatinum (II) | Q69025482 | ||
| Improved therapeutic index of methotrexate with "leucovorin rescue" | Q69114239 | ||
| Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors | Q69143021 | ||
| Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours | Q69279431 | ||
| Phenobarbital effects on cyclophosphamide pharmacokinetics in man | Q69461828 | ||
| Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function | Q69485233 | ||
| Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse | Q69488135 | ||
| A biologically active metabolite of cyclophosphamide | Q69500918 | ||
| Pharmacokinetics of methotrexate | Q69559055 | ||
| Pharmacokinetics and metabolism of adriamycin in man | Q69559062 | ||
| Mass spectrometric study of the distribution of cyclophosphamide in humans | Q69588288 | ||
| Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide | Q69733875 | ||
| Decreased Clearance of Prednisolone, a Factor in the Development of Corticosteroid Side Effects | Q69740060 | ||
| Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man | Q69753665 | ||
| Pharmacokinetics of adriamycin (NSC-123127) in patients with sarcomas | Q69768729 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 168-213 | |
| P577 | publication date | 1987-03-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Pharmacokinetics of anticancer drugs in children. | |
| P478 | volume | 12 |
| Q28325373 | Acute Hepatotoxicity after High-Dose Methotrexate Administration to Rats |
| Q33913894 | Adaptive control methods for the dose individualisation of anticancer agents |
| Q50056608 | Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. |
| Q43792801 | Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients |
| Q41845046 | Body surface area estimation in children using weight alone: application in paediatric oncology |
| Q80556570 | Can the genotoxicity of chemotherapy be predicted? |
| Q51549131 | Challenges and opportunities in childhood cancer drug development. |
| Q39647429 | Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity |
| Q39513605 | Clinical pharmacokinetics of doxorubicin |
| Q38649105 | Clinical pharmacokinetics-pharmacodynamics of anticancer drugs |
| Q38700644 | Clinical pharmacology of cancer chemotherapy in children. |
| Q52166468 | Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report. |
| Q40694511 | Pharmacokinetic drug interactions with anticancer drugs. |
| Q37951561 | Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology |
| Q35030779 | Pharmacokinetics in the child |
| Q43973231 | Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study |
| Q44747068 | Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology |
| Q77761715 | Practical treatment guide for dose individualisation in cancer chemotherapy |
| Q37671241 | Principles of treatment of pediatric solid tumors |
| Q67891361 | Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction |
| Q40694954 | Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry |
Search more.